Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy.


Journal

The FEBS journal
ISSN: 1742-4658
Titre abrégé: FEBS J
Pays: England
ID NLM: 101229646

Informations de publication

Date de publication:
06 2019
Historique:
received: 03 01 2019
revised: 19 02 2019
accepted: 21 03 2019
pubmed: 25 3 2019
medline: 16 5 2020
entrez: 24 3 2019
Statut: ppublish

Résumé

Four TEAD transcription factors (TEAD1-4) mediate the signalling output of the Hippo pathway that controls organ size in humans. TEAD transcriptional activity is regulated via interactions with the YAP, TAZ and VGLL proteins. A mutation in the TEAD1 gene, Tyr421His, has been identified in patients suffering from Sveinsson's chorioretinal atrophy (SCA), an autosomal dominant eye disease. This mutation prevents the YAP/TAZ:TEAD1 interaction. In this study, we measure the affinity of YAP, TAZ and VGLL1 for the four human TEADs and find that they have a similar affinity for all TEADs. We quantitate the effect of the mutation found in SCA patients and show that it destabilizes the YAP/TAZ:TEAD interaction by about 3 kcal·mol

Identifiants

pubmed: 30903741
doi: 10.1111/febs.14817
doi:

Substances chimiques

Cell Cycle Proteins 0
DNA-Binding Proteins 0
Intrinsically Disordered Proteins 0
Nuclear Proteins 0
TEA Domain Transcription Factors 0
TEAD1 protein, human 0
Transcription Factors 0
VGLL1 protein, human 0
YY1AP1 protein, human 0
Acyltransferases EC 2.3.-
TAFAZZIN protein, human EC 2.3.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2381-2398

Informations de copyright

© 2019 Federation of European Biochemical Societies.

Auteurs

Fedir Bokhovchuk (F)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Yannick Mesrouze (Y)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Aude Izaac (A)

Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Marco Meyerhofer (M)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Catherine Zimmermann (C)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Patrizia Fontana (P)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Tobias Schmelzle (T)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Dirk Erdmann (D)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Pascal Furet (P)

Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Joerg Kallen (J)

Chemical Biology & Therapeutics, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Patrick Chène (P)

Disease Area Oncology, Novartis Institutes for Biomedical Research, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH